BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 32698195)

  • 1. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
    Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
    Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
    An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
    Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 5. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Cull G; Burger JA; Opat S; Gottlieb D; Verner E; Trotman J; Marlton P; Munoz J; Johnston P; Simpson D; Stern JC; Prathikanti R; Wu K; Novotny W; Huang J; Tam CS
    Br J Haematol; 2022 Mar; 196(5):1209-1218. PubMed ID: 34915592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
    Owen RG; McCarthy H; Rule S; D'Sa S; Thomas SK; Tournilhac O; Forconi F; Kersten MJ; Zinzani PL; Iyengar S; Kothari J; Minnema MC; Kastritis E; Aurran-Schleinitz T; Cheson BD; Walter H; Greenwald D; Chen DY; Frigault MM; Hamdy A; Izumi R; Patel P; Wei H; Lee SK; Mittag D; Furman RR
    Lancet Haematol; 2020 Feb; 7(2):e112-e121. PubMed ID: 31866281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
    Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
    Dimopoulos MA; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Garcia-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Chan WY; Schneider J; Allewelt H; Patel S; Cohen A; Tam CS
    J Clin Oncol; 2023 Nov; 41(33):5099-5106. PubMed ID: 37478390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
    Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
    Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.
    Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Zhou D; Tam CS; Simpson D; Wang M; Phillips TJ; Opat S; Huang Z; Lu H; Song Y; Song Y
    J Hematol Oncol; 2021 Oct; 14(1):167. PubMed ID: 34649571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia].
    Tao Y; Xu YL; Wang S; Wang L; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):490-494. PubMed ID: 37550205
    [No Abstract]   [Full Text] [Related]  

  • 17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
    Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.